Navigation Links
Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
Date:5/7/2009

oximately $11.1 million for fiscal year 2010, compared to fiscal year 2009.

The Company now anticipates that with current cash, cash equivalents and marketable securities along with interest earned thereon, expected payments from Symphony Allegro, the proceeds from option exercises, and purchases of common stock pursuant to its Employee Stock Purchase Plan, the Company will be able to maintain its currently planned operations through the first quarter of 2010. Changing circumstances may cause the Company to consume capital significantly faster or slower than currently anticipated.

Alexza's Consolidated Statements of Operations include the operations of Symphony Allegro, Inc., its variable interest entity. In January 2009, the Company adopted the provisions of Statement of Financial Accounting Standards, No. 160. Under SFAS 160, the Company no longer reverses from our net loss from operations the "Loss attributed to noncontrolling interest in Symphony Allegro, Inc." This is now reported as a line item below the net loss calculation. Net loss attributable to noncontrolling interests in Symphony Allegro was $5.2 million and $3.8 million in the three months ended March 31, 2009 and 2008, respectively.

Product Candidates Development Update

- AZ-004 (Staccato loxapine). Alexza is developing AZ-004 for the acute treatment of agitation in patients with schizophrenia or bipolar disorder. The Company projects an NDA submission for AZ-004 in the first quarter of 2010.

During 2008, Alexza successfully initiated, enrolled and completed its two pivotal Phase 3 clinical trials, announcing positive results from both studies. During 2009, Alexza has five non-pivotal safety and NDA-supporting studies to conduct, which are intended to complete the Company's NDA clinical work. During the first quarter, Alexza completed a Phase 1 placebo-controlled study in 30 healthy subjects to assess
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
2. Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches
3. Alexzas AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
4. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
5. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
6. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
7. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
8. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
9. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
10. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
11. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ... the past decade has seen the atopic ...
(Date:1/15/2014)... 15, 2014  A novel wearable injector slightly larger ... and painless for patients to self-inject prescription drugs in ... of disorders, including cancer, blood diseases, autoimmune deficiencies, and ... market is expected to grow to $220B by 2018, ... a new type of injector that does not exist ...
(Date:1/14/2014)... 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), a ... it acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... terms of the acquisition were not disclosed. ... providing a wide range of sleep, mobility, and respiratory products ... and Pittsburgh markets. Progressive was founded ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... N.J., Dec. 7, 2011 Updated results of ... plus exemestane, a hormonal therapy, show everolimus provided ... without their disease progressing (progression-free survival)(1). ... months of follow-up, were presented at the 2011 ...
... Dec. 7, 2011 Jia-Hwa Fang, Ph.D., has ... Manufacturing.  In this new role, he will lead ... Laboratory Practice (GLP), and pilot formulations for early ... Manufacturing Practices (GMP).  He will be responsible for ...
Cached Medicine Technology:New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth 2New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth 3New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth 4New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth 5New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth 6New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth 7New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth 8New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth 9New Data Confirms Novartis Drug Afinitor® Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth 10Jia-Hwa Fang Joins SRI Biosciences as Director of Clinical Manufacturing 2
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... and P4 have clear and distinct effects on inflammatory ... infection. Recently, Ohtani et al., have shown a protective ... Other studies have demonstrated that E2 and P4 have ... been reported in human, mouse and rat stomach. However, ...
... Allergy Testing in Improving Asthma ... ... Health announced today,that it has entered a co-promotion agreement with Phadia, ... in the diagnosis,and treatment of asthma and other respiratory diseases. Under ...
... Oct. 31 In the final 72-hours of,this ... volunteers,across the country are joining 4,000 SEIU members, ... the job to bring home victory for,Barack Obama, ... working,families need., SEIU,s major GOTV operations are ...
... an exaggerated intestinal immune response to otherwise innocuous ... plays a key role in the pathophysiology of ... yet emerged. Vitamin E is a major lipophilic ... which protects membrane lipids from peroxidation by scavenging ...
... to sign up online at http://www.diabetesatlanta.org , ATLANTA, ... than 600,000 Georgians, could be present in more than,300,000 more, ... disease?, No. The answer is diabetes., And, new ... the U.S. has,nearly doubled in the past 10 years - ...
... Array of Colors and,Custom Products Giving Confident Wearers ... PISCATAWAY, N.J., Oct. 31 Siemens Hearing,Instruments, Inc., ... States, continues their commitment to personalizing solutions for,those ... hearing instruments,were announced at this year,s International Congress ...
Cached Medicine News:Health News:Estrogen and progesterone receptor isoforms expression in the stomach of Mongolian gerbils 2Health News:Estrogen and progesterone receptor isoforms expression in the stomach of Mongolian gerbils 3Health News:Nation's #1 Respiratory Hospital Enters Agreement to Co-Promote IgE Blood Testing 2Health News:In Final 72-Hour Push, SEIU Members Get Out The Vote for Barack Obama and Other Working Family Candidates Across the Country 2Health News:Can rectal vitamin E induce remission in patients with mild to moderate ulcerative colitis? 2Health News:As Diabetes Reaches Epidemic Levels in Georgia and U.S., Thousands Drawn to Diabetes University in Atlanta Nov. 8 2Health News:Siemens Launches Motion(TM), a Complete Product Portfolio for Mild Through Severe Hearing Loss 2Health News:Siemens Launches Motion(TM), a Complete Product Portfolio for Mild Through Severe Hearing Loss 3Health News:Siemens Launches Motion(TM), a Complete Product Portfolio for Mild Through Severe Hearing Loss 4
For the quantitative determination of total cholesterol in human serum....
Intended for the quantitative determination of total cholesterol in serum. Single vial, dry powder reagent. Reaction: Endpoint. Wavelength: 500 nm. Linearity: 700 mg/dL (12.9 mmol/L)....
For the quantitative in vitro determination of lithium in serum and plasma. Wavelength: 550 nm. Linear range: up to 4 mm....
This True 12-bit integrated and cooled system is a completely self contained unit built with a long list of standard features including all-electronic-variable transilluminator and EPI lighting....
Medicine Products: